Corbus Pharmaceuticals (CRBP) director sells 2,026 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Corbus Pharmaceuticals director Winston Kung sold 2,026 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $7.9137 per share, with individual sale prices ranging from $7.71 to $7.97.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. After this transaction, Kung holds 12,140 shares directly, which includes 3,800 unvested restricted stock units subject to the grant’s vesting schedule.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 2,026 shares ($16,033)
Net Sell
1 txn
Insider
Kung Winston
Role
null
Sold
2,026 shs ($16K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, par value $0.0001 per share | 2,026 | $7.9137 | $16K |
Holdings After Transaction:
Common Stock, par value $0.0001 per share — 12,140 shares (Direct, null)
Footnotes (1)
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.
Key Figures
Shares sold: 2,026 shares
Weighted average sale price: $7.9137 per share
Sale price range: $7.71–$7.97 per share
+3 more
6 metrics
Shares sold
2,026 shares
Open-market sale on June 10, 2026
Weighted average sale price
$7.9137 per share
Common stock sale
Sale price range
$7.71–$7.97 per share
Multiple transactions within range
Shares held after sale
12,140 shares
Direct ownership following transaction
Unvested RSUs included
3,800 RSUs
Part of post-transaction holdings
10b5-1 plan adoption date
March 11, 2026
Plan governing the reported sale
Key Terms
Rule 10b5-1 trading plan, weighted average price, restricted stock units, open-market sale
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock units financial
"This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What did Corbus Pharmaceuticals (CRBP) director Winston Kung report in this Form 4?
Director Winston Kung reported selling 2,026 shares of Corbus Pharmaceuticals common stock. The sale was an open-market transaction executed under a Rule 10b5-1 trading plan and left him with 12,140 shares, including 3,800 unvested RSUs.
What type of security did Winston Kung trade in Corbus Pharmaceuticals (CRBP)?
Winston Kung traded Corbus Pharmaceuticals common stock with a par value of $0.0001 per share. The Form 4 notes this was a non-derivative security transaction, distinct from any options or other derivative instruments.